Hasil Pencarian - Ryan J Sullivan

Perbaiki Hasil
  1. 1
    BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance

    BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance oleh Ryan J. Sullivan, Keith T. Flaherty

    Diterbitkan 2011-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Residual Hemothorax after Chest Tube Placement Correlates with Increased Risk of Empyema Following Traumatic Injury

    Residual Hemothorax after Chest Tube Placement Correlates with Increased Risk of Empyema Following Traumatic Injury oleh Riyad Karmy-Jones, Michele Holevar, Ryan J Sullivan, Ani Fleisig, Gregory J Jurkovich

    Diterbitkan 2008-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Editorial: Toxicity Mechanism and Clinical Features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume I

    Editorial: Toxicity Mechanism and Clinical Features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume I oleh Xiangyi Kong, Ryan J Sullivan, Caisheng Wu, Lin Zhang, Lin Zhang, Lin Zhang, Yu Jiang

    Diterbitkan 2022-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017

    The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017 oleh Paolo A. Ascierto, Corrado Caracò, Jeffrey E. Gershenwald, Omid Hamid, Merrick Ross, Ryan J. Sullivan, Igor Puzanov

    Diterbitkan 2018-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Budesonide treatment for microscopic colitis from immune checkpoint inhibitors

    Budesonide treatment for microscopic colitis from immune checkpoint inhibitors oleh Michael S. Hughes, Gabriel E. Molina, Steven T. Chen, Hui Zheng, Vikram Deshpande, Riley Fadden, Ryan J. Sullivan, Michael Dougan

    Diterbitkan 2019-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis

    Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis oleh Melissa Lumish, Ryan J. Sullivan, Douglas B. Johnson, Meghan J Mooradian, Daniel Y Wang, Alexandra Coromilas, Tianqi Chen

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II

    Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II oleh Chuqi Lei, Xiangyi Kong, Xiangyi Kong, Ryan J. Sullivan, Caisheng Wu, Caisheng Wu, Dawei Wang, Lin Zhang, Lin Zhang, Lin Zhang

    Diterbitkan 2023-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development

    Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development oleh Jeffrey Sosman, Elad Sharon, Theresa LaVallee, Hussein A Tawbi, Ryan J Sullivan, Harriet M Kluger, Naiyer A Rizvi, David Feltquate

    Diterbitkan 2023-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022

    The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022 oleh Paolo A. Ascierto, Renier Brentjens, Samir N. Khleif, Kunle Odunsi, Katayoun Rezvani, Marco Ruella, Ryan J. Sullivan, Bernard A. Fox, Igor Puzanov

    Diterbitkan 2023-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    The “Great Debate” at Immunotherapy Bridge 2020, December 3rd, 2020

    The “Great Debate” at Immunotherapy Bridge 2020, December 3rd, 2020 oleh Paolo A. Ascierto, Joshua Brody, Lisa H. Butterfield, Olivera J. Finn, John Goldberg, Francesco Perrone, Ryan J. Sullivan, Bernard A. Fox, Patrick Hwu, Igor Puzanov

    Diterbitkan 2021-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors

    Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors oleh Harriet Kluger, Omid Hamid, Roberta Zappasodi, Michael Hurwitz, Hussein Tawbi, Elad Sharon, Theresa LaVallee, Rebecca A Moss, Justin F Gainor, J Carl Barrett, Ryan J Sullivan

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies

    Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies oleh James L Gulley, Harriet Kluger, Hussein Tawbi, Jeffrey Sosman, Paolo A Ascierto, Michael B Atkins, Nikhil I Khushalani, Douglas B Johnson, Timonthy A Yap, Ryan J Sullivan, David Feltquate

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs

    Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs oleh Tian Zhang, Patrick M Forde, Elad Sharon, Scot Ebbinghaus, Michael B Atkins, Mark Stewart, Ryan J Sullivan, Elizabeth Barksdale, Wendy Selig, Gina Fusaro, Damla Gunenc, Dena Battle, Robyn Burns, Marc S Hurlbert

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial

    Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial oleh Mariano Severgnini, Rizwan Haq, Anita Giobbie-Hurder, Scott J Rodig, Patrick A Ott, Evisa Gjini, Ryan J Sullivan, Donald P Lawrence, Matthew Nazzaro, Kathleen L Pfaff, Jacquelyn O Wolff, Elizabeth I Buchbinder

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy

    Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy oleh Ranee Mehra, Ina Rhee, Naiyer Rizvi, Robert L Ferris, Hussein Tawbi, Matthew D Hellmann, Sarah B Goldberg, Ryan J Sullivan, Helen X Chen, Jong Chul Park, Foluso O Ademuyiwa, Z Alexander Cao

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma

    Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma oleh Kuang Du, Shiyou Wei, Zhi Wei, Dennie T. Frederick, Benchun Miao, Tabea Moll, Tian Tian, Eric Sugarman, Dmitry I. Gabrilovich, Ryan J. Sullivan, Lunxu Liu, Keith T. Flaherty, Genevieve M. Boland, Meenhard Herlyn, Gao Zhang

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations

    Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations oleh Benjamin C. Park, Sathya Narayanan, Alexander Gavralidis, Fei Ye, Run Fan, Ryan J. Sullivan, Genevieve Boland, Kerry L Reynolds, Justin M. Balko, Matteo S. Carlino, Georgina V. Long, Leyre Zubiri, Alexander M. Menzies, Douglas B. Johnson

    Diterbitkan 2023-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma

    A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma oleh Meghan J. Mooradian, Alexandre Reuben, Peter A. Prieto, Mehlika Hazar-Rethinam, Dennie T. Frederick, Brandon Nadres, Adriano Piris, Vikram Juneja, Zachary A. Cooper, Arlene H. Sharpe, Ryan B. Corcoran, Keith T. Flaherty, Donald P. Lawrence, Jennifer A. Wargo, Ryan J. Sullivan

    Diterbitkan 2018-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor–Associated Myocarditis

    Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor–Associated Myocarditis oleh Zsofia D. Drobni, Amna Zafar, Leyre Zubiri, Daniel A. Zlotoff, Raza M. Alvi, Charlotte Lee, Sarah Hartmann, Hannah K. Gilman, Alexandra‐Chloe Villani, Anju Nohria, John D. Groarke, Ryan J. Sullivan, Kerry L. Reynolds, Lili Zhang, Tomas G. Neilan

    Diterbitkan 2020-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade

    Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade oleh Douglas B. Fox, Richard Y. Ebright, Xin Hong, Hunter C. Russell, Hongshan Guo, Thomas J. LaSalle, Ben S. Wittner, Nicolas Poux, Joanna A. Vuille, Mehmet Toner, Nir Hacohen, Genevieve M. Boland, Debattama R. Sen, Ryan J. Sullivan, Shyamala Maheswaran, Daniel A. Haber

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: